Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial

By Adriano Marchese

Eikon Therapeutics shares rose Monday after the company dosed the first patient in a key registrational trial for its first-line therapy lung cancer treatment.

Shares are 10% higher at $9.80.

The late-stage biopharmaceutical company said the first patient has been dosed in the phase 2/3 TeLuRide-008 registrational study evaluating EIK1001 in combination with pembrolizumab and chemotherapy as first-line therapy for treatment-naive patients with stage 4 non-small cell lung cancer.

The study is being conducted in two phases and will be analyzed in three parts, focused on dose optimization, dose expansion and confirmatory hypothesis testing.

The TeLuRide-008 study is the second registrational phase 2/3 trial for the treatment. Another study, TeLuRide-006 which is currently enrolling patients with advanced malignant melanoma, was initiated in May of last year.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 27, 2026 10:22 ET (14:22 GMT)